Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
DATE PUBLISHED: 2021 Dec 23
JOURNAL:J Allergy Clin Immunol
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/34954198?dopt=Abstract
Chronic urticaria (CU) is a debilitating mast cell-driven disease, often refractory to standard therapy (i.e., antihistamines). Lirentelimab, an anti-Siglec-8 monoclonal antibody, selectively inhibits mast cells and depletes eosinophils.